The $22 billion gold rush.
Lenzner
Robert
R
Maiello
Michael
M
D019440:Anti-Obesity Agents / Q000009:adverse effects*; D035881:Compensation and Redress / Q000331:legislation & jurisprudence*; D020372:Dexfenfluramine / Q000009:adverse effects*; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence*; D005104:Expert Testimony / Q000191:economics; D018166:Health Care Reform; D006801:Humans; D007603:Jurisprudence; D033241:Lawyers; D016365:Liability, Legal / Q000191:economics*; D017366:Serotonin Receptor Agonists / Q000009:adverse effects*; D014481:United States
D019440:Anti-Obesity Agents; D017366:Serotonin Receptor Agonists; D020372:Dexfenfluramine